Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02201953 · ClinicalTrials.gov registry record · Phase 3

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

A Phase 3 study of Hepatitis C Virus Infection, sponsored by Gilead Sciences.

Completed
Registry status
Phase 3
Development phase
558
Enrollment target
20
Study locations

NCT02201953 is a Phase 3 study of Hepatitis C Virus Infection that has completed, run by Gilead Sciences. The registered enrollment target is 558 participants, above the 91-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (513% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02201953, a Phase 3 study of Hepatitis C Virus Infection, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 3
Development phase
558 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to compare the efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks with that of sofosbuvir (SOF) + ribavirin (RBV) for 24 weeks and to evaluate the safety and tolerability of each treatment regimen in participants with chronic genotype 3 hepatitis C virus (HCV) infection.

Conditions Studied

Hepatitis C Virus Infection

Interventions

  • DRUG SOF
  • DRUG RBV
  • DRUG SOF/VEL

Study Locations (20)

Florida

  • - Gainesville
  • - Jacksonville
  • - Miami
  • - Orlando
  • - Wellington

California

  • - Los Angeles
  • - Los Angeles
  • - Sacramento
  • - San Diego

New York

  • - New York
  • - The Bronx

Colorado

  • - Aurora

Georgia

  • - Marietta

Illinois

  • - Chicago

Indiana

  • - Indianapolis

Maryland

  • - Lutherville

Trial Details

FieldValue
Enrollment Target 558 participants
Start Date 2014-07
Est. Completion 2015-12
Phase Phase 3

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02201953

The ClinicalTrials.gov registry entry for NCT02201953 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (513% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C Virus Infection appearing as the primary indexed condition, and to 3 interventions - of which SOF is the first listed.

NCT02201953 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT02201953 about?

NCT02201953 is a clinical study titled "Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection". The primary objectives of this study are to compare the efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks with that of sofosbuvir (SOF) + ribavirin (RBV) for 24 weeks and to evaluate the safety and tolerability of each treatment regimen in particip...

What is the current status of trial NCT02201953?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2014-07. Estimated completion is 2015-12.

What conditions does trial NCT02201953 study?

This clinical trial studies the following conditions: Hepatitis C Virus Infection.

What interventions are being tested in trial NCT02201953?

The interventions under investigation include: SOF (DRUG), RBV (DRUG), SOF/VEL (DRUG).

Who is sponsoring clinical trial NCT02201953?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02201953 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C Virus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C Virus Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.